VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITEDSET: VIBHA🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED

Telephone

0-2561-1111, 0-2561-1258-67

Website

http://www.vibhavadi.com

Email

cs@vibhavadi.com

Dividend Policy

Dividend Policy

The Company has a policy to pay dividends at a rate of not less than 50% of its net profit after corporate income tax and all types of reserves as stipulated by law and the Company. However, such dividend payments will take into consideration the following factors: the Company's operating results, financial position, liquidity, investment plans of the Company and its subsidiaries, and other factors related to the Company's management and future business expansion. The aforementioned dividend payments must be approved by the Board of Directors and the shareholders' meeting, with the exception of interim dividend payments which are approved by a resolution of the Board of Directors' meeting.

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years Ago4 Years AgoMetricDescription
0.10.060.070.090.07Net profit per share (Baht : Share)Net profit per share (baht : share)
0.060.050.050.060.05Dividend per share (Baht : Share)Dividend per share (baht : share)
00000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
00000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
0.060.050.050.060.05Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
60.8983.0372.9964.1875.3Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Major Shareholders

No.NameShares% Shares
29,802F&S 79 Co., Ltd.2,420,700,52117.95
29,803MR. CHAISITH VIRIYAMETTAKUL2,038,000,00015.11
29,804SYNPHATE Co., Lte1,170,480,9668.68
29,805RAMKHAMHAENG HOSPITAL l PLC.962,605,2007.14
29,806CHOPHYA HOSPITAL l Plc.804,634,1955.97
29,807MR. PISUTH VIRIYAMETTAKUL674,249,6005
29,808Vibharam Hospital Co., Ltd.564,043,1334.18
29,809MR. PHIJIT WIRIYAMETTAKUL478,800,0003.55
29,810MR. PHICHIT WIRIYAMETTAKUL306,960,0002.28
29,811MR. PIPAT VIRIYAMETTAKUL274,100,0002.03
29,812Ms. Niramon WIRIYAMETTAKUL137,520,0001.02
29,813MR. VIBOON WADCHARASURANG117,970,7430.87
29,814MR. PRAMUK UNAJAK100,000,0000.74
29,815MR.SONG WATCHARASRIROJ81,300,0000.6

Business Strategies Overview

Introduction

The Company aims to be a leading private hospital with outstanding characteristics within 5 years in terms of quality medical care, service, and personnel, under the framework of professional ethics that conducts its business with good governance, as well as caring about the environment and society. In this regard, the Board of Directors and the Company’s executives have jointly established the following vision, mission, values, and objectives:

Vision

“Committed to becoming a tertiary care provider driven by high quality health care and excellent service.”

Mission

  • To continuously develop to provide tertiary care through our Centers of Excellence.

  • To implement Smart Service / Smart Operation / Smart Hospital systems that support process optimization.

  • To gain customer trust through a service-oriented culture with happy employees

  • To continuously improve to bring the most value in the interest of our stakeholders, social environment, and governance.

Chairman's Message

Message from the Chairman of the Board of Directors

In the past year, the private hospital industry has continued to face several challenges, including economic volatility, rising medical costs, rapid technological changes, and increasing expectations of patients. Vibhavadi Hospital Public Company Limited (the “Company”) has continuously adapted its strategies to maintain competitiveness, while conducting its business with prudence under the principles of good corporate governance, alongside systematically enhancing the quality of medical treatment and services. The Company has demonstrated its commitment to continuous improvement and adaptability amid rapid changes in the economic, social, and technological landscape. As a result, in the past year, the Company was recognized as a constituent of the Thailand Sustainability Investment (SET ESG Ratings) with a rating of “A”, achieved an “Excellent” CGR score, and continued its membership in the Collective Action Against Corruption (CAC) Company’s strong commitment to sustainable and ethical business practices.

The Company places great importance on comprehensive risk management and is committed to driving the organization toward sustainable growth in line with international standards, with a focus on three key pillars:

Environmental (Environment): We strive to minimize environmental impact through efficient energy utilization, the initiation of greenhouse gas reduction projects, and responsible medical waste management.

Social (Social): We emphasize the quality of life of patients, medical personnel, and surrounding communities by enhancing service standards, promoting equitable access to healthcare, and ensuring workplace safety.

Governance (Governance): We conduct our business in accordance with good corporate governance principles—ensuring transparency, accountability, and consideration of all stakeholders—while fostering an organizational culture grounded in ethics and responsibility.

The Board of Directors and the management team remain committed to driving the Company toward sustainable and stable growth. For the year 2025, the Company reported total revenue of Baht 6,106.22 million, with hospital operation revenue of Baht 5,538.23 million, and net profit of Baht 1,813.16 million. As of December 31, 2025, the Company had total assets of Baht 21,678.27 million, total liabilities of Baht 9,202.10 million, and shareholders’ equity of Baht 12,476.17 million.

For 2026, Vibhavadi Hospital has established strategies to strengthen the organization for long-term growth, focusing on advancing medical excellence, adopting modern and high-efficiency technologies for treatment, and enhancing cost management efficiency. At the same time, the Company continues to emphasize sustainability and resilience in order to maintain competitiveness and deliver appropriate returns to shareholders.

On behalf of the Board of Directors, I would like to express our sincere appreciation to our customers, shareholders, business partners, and all stakeholders for their continued trust and support. I would also like to extend my gratitude to the management team, medical professionals, and all employees for their dedication and professionalism, as well as their service-minded commitment to patients. Together, we continue to create sustainable value for the business while upholding our responsibilities to society, communities, and the environment for enduring growth.

-Nikom Wairatpanij-

(Mr. Nikom Wairatpanij)

Chairman of the Board of Directors

Vibhavadi Medical Center Public Company Limited.

Vision

  • Committed to becoming a tertiary care provider driven by high quality health care and excellent service.

Objectives

  • To continuously develop to provide tertiary care through our Centers of Excellence.

  • To implement Smart Service / Smart Operation / Smart Hospital systems that support process optimization.

  • To gain customer trust through a service-oriented culture with happy employees

  • To continuously improve to bring the most value in the interest of our stakeholders, social environment, and governance.

Goals

The Company aims, within the next five years, to become a leading private hospital distinguished by excellence in medical treatment, service quality, and the quality of its personnel.

Business Strategies

In 2025, Vibhavadi Hospital focused on expanding its growth through the development of specialized medical centers, with an emphasis on investing in advanced medical technologies and skilled personnel in order to create differentiation and enhance treatment efficiency. The Hospital is also committed to conducting its business in accordance with ESG principles to achieve sustainable growth.

In 2025, Vibhavadi Hospital implemented its corporate strategies, including the establishment of a Gamma Knife Center for the treatment of brain disorders, the opening of Vibhavadi Hospital 2, and the promotion of business expansion through its subsidiaries. The Company also conducted its operations with due regard to environmental and social responsibilities, while adhering to good corporate governance principles. As a result, the Company received a SET ESG Rating of “A” for the year 2025.

Other Information

NameDescription
Organizational Values

Safety

Conduct regular self-assessment of the safety and quality of medical services delivered to patients, as well as results delivered to colleagues.

Mindfulness

Have an understanding of the needs and expectations of internal and external service recipients, including providing service with enthusiasm, sincerity, politeness, speed, and respect to service recipients as though they were relatives, as well as displaying Excellence Services Behavior (ESB) at an appropriate level.Excellence

Cooperate

Have an understanding of the scope, duties, and responsibilities of one’s own role as a team member, listen to the opinions of colleagues, participate in solving problems, exchange experiences and opinions, to ensure that everyone can work effectively together toward the organization’s goal

Honesty

Honesty toward oneself, one’s profession, service recipients, co-workers, and the organization

Development

Apply knowledge, abilities, skills, attitudes, as well as risk management across all aspects, that leads toward continuous service improvement and development.

Pursue Knowledge

Develop knowledge and abilities of personnel to enhance work skills, as well as being able to apply technology effectively and increase learning channels comprehensively to all personnel.

Toward Excellence

Promote excellence in providing healthcare, academics, personnel, and service, including equipment, and buildings, as well as providing efficient coordination to service recipients.

Material Changes & Developments

Introduction

The Company has continuously undergone changes and development, which can be categorized into three key areas as follows:

  1. Changes in Capital Structure and Management: These include the share repurchase program for financial management, the Vibhavadi Hospital 2 project, the divestment of investments in ordinary shares of an indirect subsidiary, and the issuance of warrants (VIBHA-W5).

  2. Improvements in Hospital Quality and Services: These include the establishment of the Customer Experience Service unit and the Patient Experience and Customer Service unit, as well as the development of a Center of Excellence in Dental Care.

  3. Development in Technology and Facilities: These include the procurement of medical equipment, renovation of patient rooms, expansion of Jab & GO clinic branches, and the establishment of a Gamma Knife Center.

Material Changes & Developments

YearDescription
2,023

1. Changes in Capital Structure and Management

  • The Company reduced its registered capital by Baht 101,235,022.40 through the cancellation of up to 1,012,350,224 unissued ordinary shares. These shares were originally reserved for the exercise of Warrants No. 3 (VIBHA-W3), which have expired.

2. Changes in Hospital Quality Development and Services

  • The Company established a Customer Experience Service Unit and conducted service training programs for employees and nursing staff to enhance service efficiency and improve patient care quality.

  • The Company also improved the operations of its Dental Center in terms of treatment and service delivery, aiming to develop it into a center of excellence.

3. Changes in Technology and Facilities

  • The Company invested in a Femto LASIK system, utilizing laser technology for all stages of the procedure—from corneal flap creation to corneal reshaping—without the use of blades, resulting in faster recovery for patients.

  • The Company renovated inpatient rooms on the 7th–8th floors of Building 1 at Vibhavadi Hospital to enhance modernity, comfort, and competitiveness with nearby hospitals.

  • In addition, the Company further enhanced the Dental Center by improving treatment quality, service delivery, and management practices, with a focus on delivering the best possible patient experience through high-quality dental care and attentive services.

  • The Company also established a Patient Experience and Customer Service Unit, along with organizing service training programs for employees and nurses, emphasizing the development of high-quality service skills to ensure excellent patient experiences. Furthermore, the Company focused on developing seamless service procedures to ensure efficient and smooth patient care processes.

  • Finally, the Company strengthened its corporate image and brand by enhancing service quality in line with international standards, reinforcing confidence in its medical excellence and patient care, and building trust among patients and customers across all segments.

2,024
  1. Changes in Capital Structure and Management

  • At the Board of Directors’ Meeting No. 1/2024 held on 29 February 2024, a resolution was passed approving a share repurchase program for financial management purposes, with a total budget not exceeding Baht 1,200 million and not exceeding 540 million shares, representing 3.98% of the total issued shares. The repurchase was conducted through the trading system of the Stock Exchange of Thailand during the period from 4 March 2024 to 4 September 2024.

  • As of the end of the program, the Company repurchased a total of 91,400,000 shares, representing 0.67% of the total issued shares, with a total value of Baht 194,232,974. The Company may resell the repurchased shares after a period of 3 months from the completion date of the repurchase and within 3 years from the end of the program. If the Company is unable to sell all repurchased shares within the specified period, it will proceed with a capital reduction by canceling the remaining treasury shares.

  • In addition, the Company initiated the Vibhavadi 2 Project with an investment budget of Baht 1,200 million, comprising 59 beds. The project is located on Highway No. 35 (Thonburi–Pak Tho Road, Rama 2 Road), targeting communities in Samut Sakhon Province. In addition to general medical services, the project includes a high-efficiency LINAC radiotherapy center and a nuclear medicine center to support cancer patients in the area and nearby regions. The project is expected to be completed within 2025.

  1. Changes in Hospital Quality Development and Services

  • The Company launched “Jab & Go Clinic”, providing vaccination services, medical check-ups for issuance of medical certificates, and sales of the Hospital’s cosmeceutical products at BTS Phaya Thai and BTS Ploenchit stations.

  • Vibhavadi also increased its registered bed capacity from 258 beds to 300 beds to enhance service capability.

Changes in Technology and Facilities

  • The Company renovated patient rooms in Building 1 to enhance customer satisfaction, with room designs incorporating environmentally friendly materials and complying with hospital standards.

  • The Company also co-invested with Healthcare Therapeutics Co., Ltd. to introduce Gamma Knife radiosurgery technology for the treatment of brain tumors and established the Siam Gamma Knife Therapy Center, the only center in Thailand utilizing the globally recognized Leksell Gamma Knife technology.

  • In addition, the Company procured advanced medical equipment to enhance treatment capabilities, such as:

    V Beam Perfecta Laser (Skin treatment) high-definition laparoscopic imaging transmission system

    High-resolution endoscopy systems

  • The Company further expanded Jab & Go Clinic branches at Phaya Thai and Ploenchit, offering vaccination and medical consultation services. The clinics were designed in line with the Hospital’s rebranding concept to reflect a modern image, along with the sale of high-quality cosmeceutical products to meet urban lifestyle needs.

  • The Company has strengthened its corporate image and brand identity through the use of its Corporate Identity (CI) color scheme, emphasizing a modern, friendly, and professional image in healthcare services. Facilities have been continuously improved to ensure cleanliness, modernity, and convenience for patients.

  • Furthermore, Vibhavadi Hospital increased its registered bed capacity from 258 to 300 beds to enhance its ability to accommodate the growing number of patients. This development strengthens the Hospital’s position as a leading healthcare provider capable of delivering comprehensive and efficient medical services. The Company also focuses on strengthening relationships and collaborations with insurance companies and business partners to expand its customer base and enhance service confidence.

2,025
  1. Changes in Capital Structure and Management

  • At the Special Board of Directors’ Meeting No. 1/2025 held on 8 September 2025, a resolution was passed approving Chiangmai Ram Hospital Co., Ltd. (a subsidiary of Chiangmai Ram Medical Business Public Company Limited, which is a subsidiary of the Company) to dispose of 4.99% of its shares in Ramkhamhaeng Hospital Public Company Limited to non-related parties. This transaction is considered a disposal of assets under the Stock Exchange of Thailand (SET) regulations. The transaction size, calculated based on net tangible assets (NTA), was 10.02%, which is classified as a small transaction and does not fall under the requirement for disclosure under the SET Notification on Acquisition or Disposal of Assets. The transaction aims to reduce risks associated with cross-shareholding and to comply with good corporate governance principles.

  • At the Board of Directors’ Meeting No. 5/2025 held on 26 September 2025, a resolution was passed approving Chiangmai Ram Hospital Co., Ltd. (an indirect subsidiary of the Company) to dispose of 4.6 million shares in Ramkhamhaeng Hospital Public Company Limited, representing 0.38% of the total issued shares, at a price of Baht 17.80 per share, totaling Baht 81.88 million, to non-related parties. The transaction size was 0.77% based on NTA. When combined with transactions over the previous six months, the total transaction size was 17.43%, classified as a Type 2 transaction (15%–50%). The Company is therefore required to disclose information to the SET and circulate a notice to shareholders within 21 days. This transaction was approved at the Extraordinary General Meeting No. 1/2025 on 19 November 2025.

  • At the same meeting, the Board also approved the disposal of 21.75 million shares (1.81%) in Ramkhamhaeng Hospital Public Company Limited at Baht 17.80 per share, totaling Baht 387.15 million, to related parties, namely Ms. Rukkhajee Kanchanapitak, Mr. Pramook Unjak, Mr. Pitchaya Somboonsin, and Mr. Thibault Spithakis. The transaction size was 3.64% (NTA basis), and when aggregated with prior transactions, totaled 17.43%, classified as a Type 2 transaction. In addition, this transaction is considered a related party transaction under Capital Market Supervisory Board Notification TorJor. 21/2551 and SET regulations, with a transaction size of 4.39% of NTA (aggregated at 8.82%). The Company has disclosed information, appointed an independent financial advisor, and obtained shareholder approval at the Extraordinary General Meeting No. 1/2025 on 19 November 2025.

  • Furthermore, the Board approved the disposal of 2,848,000 shares (7.12%) in Chiangmai Ram Hospital Co., Ltd. by Chiangmai Ram Medical Business Public Company Limited to Ramkhamhaeng Hospital Public Company Limited (a related party). The transaction size was 3.22% (based on net profit), and 17.43% when aggregated, classified as a Type 2 transaction. It is also a related party transaction with a size of 3.98% (aggregated at 8.82% of NTA). The Company has complied with disclosure requirements, appointed an independent financial advisor, and obtained shareholder approval at the Extraordinary General Meeting No. 1/2025 on 19 November 2025.

  • At the same Board meeting, approval was granted for the issuance and offering of Warrants No. 5 (VIBHA-W5) of up to 1,123,733,816 units to existing shareholders free of charge, at a ratio of 12 ordinary shares per 1 warrant. The warrants have a term of 3 years from the issuance date (15 December 2025), with an exercise ratio of 1 warrant per 1 ordinary share at an exercise price of Baht 2.00 per share. This was approved by shareholders at the Extraordinary General Meeting No. 1/2025.

  • At the Board of Directors’ Meeting No. 4/2025 held on 14 August 2025, approval was granted for the disposal of treasury shares under the share repurchase program and capital reduction for unsold shares totaling 91,400,000 shares. The shares were offered via the automatic matching system of the SET during 18–20 August 2025. As the Company was unable to sell all shares, it reduced its paid-up capital by canceling the remaining treasury shares and reducing registered capital by Baht 143,112,781, from Baht 1,491,593,360.60 to Baht 1,348,480,579.60, including amendments to Clause 4 of the Memorandum of Association.

    2. Changes in Hospital Quality Development and Services

  • The Company established the Siam Gamma Knife Therapy Center, the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology, a global standard for non-invasive treatment of brain and neurological disorders without open surgery.

    3. Changes in Technology and Facilities

  • On 11 February 2025, Vibhavadi Hospital entered into a collaboration agreement with Healthcare Therapeutics Co., Ltd., under CMC Biotech Group, to establish the Siam Gamma Knife Therapy Center, which officially commenced operations on 16 June 2025.

  • On 4 August 2025, Vibhavadi Hospital launched the “JAB&GO Clinic”, its third medical clinic, located at Metro Mall @ MRT Chatuchak, providing convenient and fast vaccination and healthcare services.

Use of Proceeds from Securities Offerings

Is There Money Raised from a Securities Offering Still to Report On?

Yes

Offerings

Type of SecuritiesType — Please SpecifyAmount Raised Given AsAmount Raised (Million Baht)Uses of the MoneyUsed as Declared?Progress / Reasons and Measures if Not Used as Declared
OtherWarrants28730.582025-07 · Objective: To support the Company’s investment opportunities and/or for working capital purposes. · Period type: 2870 · Start period: 2022-07 · Spent amount type: 2873 · Start spent amount: 0.58 · Expected amount type: 2873 · Start expected amount range: 3393.97Y

The Company raised funds through the issuance of Warrants No. 4 (VIBHA-W4) totaling 1,131,322,132 units, with an exercise price of Baht 3 per share. The warrants were allocated to the Company’s existing shareholders. The final exercise date was 18 July 2025, with 194,322 units exercised, representing proceeds of Baht 582,966.

The proceeds received were utilized as working capital for the Company’s operations, in accordance with the stated objectives.

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

Yes

Commitments and How They Were Met

The Company issued and offered for sale warrants to purchase ordinary shares of the Company in the amount of 1,123,729,289 units, allocated to the existing ordinary shareholders of the Company. The details of the warrants are as follows:

Type

Warrants to purchase ordinary shares of Vibhavadi Hospital Public Company Limited No. 5 (VIBHA-W5)

Nature of Securities

Registered and transferable warrants

Number of Warrants Issued

Not exceeding 1,123,729,289 units

Offering Price per Unit

Baht 0 (Zero Baht) per unit

Exercise Ratio

One (1) unit of VIBHA-W5 warrants entitles the holder to purchase one (1) newly issued ordinary share of the Company (subject to adjustment in accordance with the terms and conditions of the warrants)

Exercise Price

Baht 2.00 per share (subject to adjustment in accordance with the terms and conditions of the warrants)

Issue Date

December 15, 2025

Expiration Date

December 14, 2028

Term of Warrants

3 years from the issue date of VIBHA-W5 warrants

Exercise Period

The warrants may be exercised on the last business day of March and September throughout the term of the warrants. The first exercise date is March 31, 2026. Any unexercised warrants or those not exercised on any exercise date may be accumulated for exercise on subsequent exercise dates throughout the term of the warrants. Any warrants remaining unexercised upon expiration shall be cancelled and become null and void. The final exercise date shall be the date on which the warrants reach their three-year term. If such date is not a business day of the Company, the exercise date shall be moved to the preceding business day.

Period for Notification of Intention to Exercise

Warrant holders wishing to exercise their rights to purchase ordinary shares must submit their intention to exercise within five (5) business days prior to each exercise date. If the exercise date falls on a non-business day of the Company, the exercise date shall be moved to the last preceding business day. For the final exercise, the intention to exercise must be submitted at least fifteen (15) days prior to the final exercise date.

Secondary Market for Warrants

The Stock Exchange of Thailand

Secondary Market for Ordinary Shares Resulting from the Exercise of Warrants

The Company will list the ordinary shares arising from the exercise of these warrants on the Stock Exchange of Thailand

Warrant Registrar

Thailand Securities Depository Company Limited

Dividend Policy of the Company

The Company has a policy to pay dividends at a rate of not less than 50% of its net profit after corporate income tax and all types of reserves as required by law and the Company. However, such dividend payments will depend on various factors, including the Company’s operating results, financial position, liquidity, investment plans of the Company and its subsidiaries, and other relevant factors relating to business operations and future expansion. Such dividend payments must be approved by the Board of Directors and the shareholders’ meeting, except for interim dividends, which may be approved by the Board of Directors.

Group Operating-Structure Policy

Description

Vibhavadi Medical Center Public Company Limited and its subsidiaries hold investments in several other private hospitals, including Ramkhamhaeng Hospital, Synphaet Hospital, Chaophya Hospital, and Vibhharam Hospital. Nevertheless, each hospital within the group maintains a good relationship and acts as a business partner to one another. This is because each hospital is located in different areas, and the Company has an investment policy requiring that each investment be located at least 10 kilometers apart.

For investments in the northern region, the Company assigns Chiangmai Ram Medical Business Public Company Limited, a subsidiary, to undertake such investments on its behalf. Historically, the major shareholder group has operated with mutual support and cooperation, including the exchange of information, joint negotiations with business partners (e.g., procurement of materials and equipment), personnel training, and academic collaboration, in order to achieve maximum benefits for the Company. In addition, there is a referral system among hospitals within the group, whereby patients may be transferred to hospitals with greater readiness or specialization, or when appropriate, such as in cases where a hospital is unable to accommodate patients.

The Policy on Management of Conflict of Interest In cases where the major shareholder (F&S 79 Co., Ltd. or “F&S”) holds shares in other companies engaged in the same business as the Company

In the event that F&S, which holds more than 10% of the Company’s shares, also holds shares in other companies operating hospital businesses similar to the Company, such shareholdings do not give rise to conflicts of interest. This is because each hospital targets different customer segments due to their distinct geographic locations. Furthermore, each hospital has different areas of specialization. For example, Ramkhamhaeng Hospital focuses on specialized excellence in areas such as the 24-hour Cardiac Center, Spine and Back Pain Center, Diabetes Center, and Neurology and Neurosurgery Center. F&S 79, which operates ear, nose, and throat (ENT) hospitals, focuses on ophthalmology, otolaryngology, and related specialties. Vibhharam Hospital primarily serves social security patients and patients under government healthcare schemes. Meanwhile, Vibhavadi Hospital focuses on specialized excellence in areas such as the Brain and Spine Center, Orthopedic Center, Gastrointestinal Center, Skin and Laser Center, Accident and Emergency Center, and Health and Occupational Health Center.

Such shareholding structures foster mutual support in both academic and operational aspects. Each hospital, however, operates independently with clearly separated management structures, policies, and operational autonomy.

In addition, the Wiriyamettakul Group, which holds approximately 27.26% of the Company’s shares, helps maintain a balance of control to safeguard the interests of the Company. The Board of Directors, Executive Committee, and management teams of each hospital are largely composed of different individuals, and the audit committees and independent directors are also distinct. Representation on the Company’s Board is based on shareholding proportion. The Wiriyamettakul Group has two representatives on the Board, both authorized signatories but not authorized to jointly sign. Ramkhamhaeng Hospital Public Company Limited has two representatives on the Board, with one authorized signatory. F&S 79 Co., Ltd. has one representative on the Board, without signing authority.

The Company has established measures to manage conflicts of interest. Any connected transactions between the Company and related parties, as defined by the Stock Exchange of Thailand, are subject to review by the Audit Committee to ensure reasonableness and appropriate pricing conditions. Such transactions are then proposed to the Board of Directors or shareholders, as the case may be. The Company strictly complies with the regulations and requirements of the Securities and Exchange Commission and the Stock Exchange of Thailand regarding connected transactions.

Over the past five years, the Company has not entered into any connected transactions with F&S or companies in which F&S is a major shareholder, except for transactions conducted in the ordinary course of business, such as the purchase and sale of medical equipment or consumable supplies.

Companies Where the Company Holds ≥10%

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneBusiness TypeSecurity TypeSharesPaid-up Shares
Chiang Mai Ram Medical Business Public Company Limited 8 Boonruangrit Road, Amphur Mueang, Chiang Mai 50200Chiang Mai50200053-399-9777Private HospitalCommon shares4,071,125,0004,071,125,000
V PRECISION Co., Ltd.1008/8 Ngamwongwan Road, Latyao, Jatujak, Bangkok 10900Bangkok10900096-964-6465Anti-Aging CenterCommon shares500,000500,000
Beauty Design Center Co., Ltd.51/45, Ngamwongwan Road, Latyao, Jatujak, Bangkok 10900Bangkok10900063-078-3779Beauty businessCommon shares4,300,0004,300,000
Fertiva Co., Ltd.1008/18, viphavadi Rangsit Road, Latyao, Jatujak, Bangkok 10900Bangkok10900085-842-1865Infertility treatment centerCommon shares12,000,00012,000,000

Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

No

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Introduction

The shareholding structure as of December 31, 2025 is as follows:

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
Chiang Mai Ram Medical Business Public Company Limited VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED · Voting rights percent: 82.57 · Shareholding proportion percent: 82.57
V PRECISION Co., Ltd.VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED · Voting rights percent: 70.0 · Shareholding proportion percent: 70.0
Beauty Design Center Co., Ltd.VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED · Voting rights percent: 46.25 · Shareholding proportion percent: 46.25
Fertiva Co., Ltd.VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITED · Voting rights percent: 96.67 · Shareholding proportion percent: 96.67

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations6,106,224.561008,997,899.681008,621,910.84100
Revenues from medical treatment5,538,278.2690.78,470,179.6894.148,100,288.8793.95
OtherOther567,946.39.3527,7205.86521,621.976.05

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue from operations6,106,224.561008,997,899.681008,621,910.84100
DomesticDomestic6,106,224.561008,997,899.681008,621,910.84100
InternationalInternational000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 567946.3 · Description: Total other income · As of yesteryear: 527720.0 · As of year before yesteryear: 521621.97 · 1711 · As of year: 567946.3 · Description: Other income from operations · As of yesteryear: 527720.0 · As of year before yesteryear: 521621.971712 · As of year: 0.0 · Description: Other income not from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01713 · As of year: 144571.83 · Description: Share of profit · As of yesteryear: 65902.61 · As of year before yesteryear: 73744.09

Product / Service Characteristics

Introduction

The Company provides medical care services to users on an outpatient and inpatient basis, and can be classified according to the services provided as of December 31, 2025, as follows:

Departments

  1. No. of Rooms / Beds

1. The Outpatient Service Center can accommodate 2,000 patients/day, and consists of

114 rooms

  • Internal Medicine Clinic

  • Respiratory System Clinic

  • Surgery Clinic

  • rthopedic Center

  • bstetrics and Gynecology Clinic

  • Accident and Emergency Center

  • Pediatric Clinic

  • Gastrointestinal Center

  • Prenatal Diagnosis Clinic

  • Infertility Treatment Center

  • Diabetes Clinic

  • Cardiac Center

  • Urology Clinic

  • Lasik Center

  • Child Development Clinic

  • Brain and Spine Center

  • Cerebrovascular Clinic

  • Skin and Laser Center

  • Psychiatric Clinic

  • Dialysis Center

  • phthalmology Clinic

  • Health and Occupational Health Center

  • Ear, Nose, and Throat Clinic

  • Dental Center

  • Neurological Disease Clinic

  • Child Development Center

2. Radiology

9 rooms

3. Department of Rehabilitation

20 beds

4. Pathology

6 rooms

5. Intensive Care Unit

13 beds

6. Semi-Intensive Care Unit

24 beds

7. Cardiac Intensive Care Unit (CCU)

11 beds

8. Neonatal

20 beds

9. Neonatal Intensive Care Unit (NICU)

3 beds

10. Delivery Room

3 beds

11. Operating Room

6 beds

12. Inpatient

300 beds

Remark: Details of the service can be found on the Company’s website https://www.vibhavidi.com/th/center

Business Type

3115

Business Groups

Business GroupDescription
Provide medical services

Vibhavadi Medical Center Public Company Limited engages in the provision of medical services.

Research & Development

Has R&D Policy (Y/N)

No

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

Assets Used in the Business

Permanent Assets — Description

As of 31 December 2025, the Company and its subsidiaries had property, plant and equipment used in their business operations, including land, buildings and building improvements, medical tools and equipment, furniture and office equipment, health center equipment and fixtures, vehicles, medical instruments and equipment, and computer software of the Company. The details are as follows:

Permanent Assets — Appraisal

AssetOwnershipObligationAppraisal ValueDescription
Land CompanyNone207.41
-
LandCompanyMortgage271.18
Land 3 rai 1 ngan 21.8 sq.wah
Building and building improvementCompanyNone341.13
-
Medical instruments and office appliancesCompanyNone142.31
-
Furniture fixture and equipmentCompanyNone39.26
-
Appliances health centerCompanyNone7.34
-
Vehicle CompanyNone18.17
-
Assets in progressCompanyOn Process408.49
-

Intangible Assets — Description

As of 31 December 2025, the Company and its subsidiaries had net intangible assets amounting to Baht 17.80 million, primarily consisting of computer software used in hospital operations. Such intangible assets are amortized and recognized as expenses in the statement of profit or loss using the straight-line method over the estimated useful lives of the assets, ranging from 5 to 10 years.

Intangible Assets — Appraisal

AssetTypeAppraisal ValueDescription
Software ComputerSoftware17.8
-

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

The Company has established a policy for managing its subsidiaries in accordance with the principles of good corporate governance. The Company appoints its representatives to serve as directors in the subsidiaries in proportion to its shareholding, in order to participate in providing opinions, formulating key policies, and overseeing the subsidiaries’ operations to ensure that they are conducted properly, appropriately, and in alignment with the policies of the Company’s Board of Directors. The operating results of the subsidiaries are also regularly reported to the Board of Directors for acknowledgment.

Marketing Policy & Competition

Introduction

The Company remains committed to maintaining high standards of service quality. It continuously enhances the quality of medical services and develops the capabilities of its medical personnel, while also investing in advanced and efficient medical technologies. In addition, the Company has established new specialized centers, including the Gamma Knife Center, which is the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology—an internationally recognized standard for the treatment of brain and neurological disorders without the need for open surgery. The Company also continues to improve its existing centers. Furthermore, the Company has launched “Jab & Go” clinics at Phaya Thai, Ploenchit, and MRT Chatuchak stations, providing vaccination services and medical consultations by physicians. These clinics are designed and decorated in alignment with the rebranding concept of Vibhavadi Hospital, reflecting a modern image. In addition, Jab & Go clinics offer high-quality cosmeceutical products developed by the hospital to cater to the lifestyle needs of customers in BTS Phaya Thai and BTS Ploenchit areas. The Company continuously reviews its operational plans to ensure efficiency, adaptability to changing circumstances, and alignment with its strategic direction, with the aim of achieving sustainable growth.

In 2025, the Hospital was recognized as one of the “Thailand’s Most Admired Company 2024–2025”, ranking 6th in the private hospital category. In addition to the above initiatives, the Company has formulated the following competitive strategies:

Marketing Strategy

The Company focuses on implementing marketing strategies to enhance its competitiveness and to accommodate the continuously increasing demand for healthcare services. It places emphasis on improving the quality of medical treatment, enhancing patient experience, and expanding business partnerships to support sustainable growth. Key initiatives include:

  1. In 2025, the Hospital expanded, renovated, and developed specialized medical centers, while adopting advanced medical technologies for diagnosis and treatment to elevate service standards and effectively meet patient needs. Examples include the development of the Health and Occupational Health Center and the establishment of the Gamma Knife Center.

  2. The Hospital continues to build partnerships by increasing shareholdings in other hospitals with strong profitability potential to expand its network and access new market segments. This also facilitates patient referrals and broadens the customer base to include middle-income patients and those with health insurance.

  3. The Hospital utilizes digital technology to communicate and disseminate healthcare information via its website and social media platforms, enabling the public to conveniently and quickly access medical services, while enhancing the Hospital’s modernity, medical expertise, and service excellence.

  4. The Hospital generates additional revenue and expands its customer base by offering healthcare products, health check-up packages, and vaccination promotions through its website. It has also established a retail outlet under the name “Doctor’s Choice by Vibhavadi”, offering hospital products, dietary supplements, and consignment cosmetics.

  5. The Hospital has partnered with other businesses to expand its customer base by launching “Jab & Go by Vibhavadi” clinics at BTS Phaya Thai, Ploenchit, and Chatuchak stations, providing affordable vaccination services, which are increasingly popular among foreign tourists in central business district (CBD) areas.

  6. The Hospital continues to implement marketing strategies to increase the proportion of international patients, particularly targeting patients from China seeking fertility treatments for a second child.

  7. The Hospital emphasizes brand-aligned communication to strengthen its position as a leading hospital. It also fosters strong relationships with insurance companies and business partners to enhance confidence in service quality and support sustainable growth opportunities.

  8. The Company actively engages with the community through public relations activities and events, such as CPR (basic life support) training, blood donation campaigns, and other health promotion initiatives. It also organizes special events for insurance companies and business partners to strengthen relationships, build trust, and reinforce its image as a key healthcare provider for the community and its partners.

  9. The Company is expanding its investment through the construction of Vibhavadi Hospital 2, with a capacity of 59 beds. Part of the project will include a specialized cancer treatment center to expand its market presence in the Rama 2 area.

    Based on these strategies, the Company is confident in its ability to enhance its competitive capabilities, strengthen patient confidence, and support stable and sustainable business growth in the long term.

Reporting Mode

3117

Marketing Policy (Overall)

In 2025, the Hospital continuously enhanced the quality of its medical services and further developed the capabilities of its medical personnel. It also invested in advanced and high-performance medical equipment. In addition, the Hospital established new specialized centers, including the Gamma Knife Center, which is the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology—an internationally recognized standard for the treatment of brain and neurological disorders without the need for open surgery.

Industry & Competition (Overall)

In 2025, the private hospital industry remained highly competitive, with an increasing number of new entrants intensifying market competition. In response, Vibhavadi Hospital has adjusted its strategies to enhance its competitiveness. These include service differentiation, the treatment of complex diseases, and the adoption of advanced medical technologies. Examples include the establishment of the Gamma Knife Center and the enhancement of the Health and Occupational Health Center, among others.

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

(1) Medical Personnel

Medical personnel are the core of the healthcare service system, driving operational efficiency and effectiveness, and contributing to the overall success of the organization. Having knowledgeable, competent, and well-prepared personnel is essential to the Company’s operations. Therefore, the Company places great importance on the recruitment and continuous development of its medical personnel.

The Company has a policy to recruit physicians with expertise in various medical specialties, as well as nurses and other medical personnel, in order to provide comprehensive and high-quality services to patients. All personnel are subject to a rigorous selection and credential verification process by the Hospital’s medical committees. Continuous training programs are provided for physicians and nurses to enhance their medical knowledge and professional competencies. In addition, nurses receive training to develop their knowledge and practical skills prior to performing their duties.

In 2025, the Company provided training and capability development programs for physicians and medical personnel, averaging 48 hours per person per year, to further improve and enhance operational systems.

(2) Procurement of Pharmaceuticals and Medical Supplies

The Company has a policy to procure pharmaceuticals and medical supplies from both domestic and international suppliers, with purchases diversified across multiple vendors. In addition, the Company has implemented a centralized procurement system for all hospitals within the group. The central procurement department consolidates purchase orders from affiliated hospitals and coordinates with suppliers for procurement.

Such an approach enhances procurement efficiency and inventory management across the group, including the evaluation of price appropriateness, effectiveness, and quality of pharmaceuticals and medical supplies.

Furthermore, in 2025, the Company continuously reviewed and improved its operational processes to ensure efficiency amid a dynamic environment. Information technology systems have been implemented to support data collection and management, enabling data analysis and further development. This enhances transparency, efficiency, and auditability of operations, while supporting sustainable growth in the future. The Company also emphasizes building strong relationships with suppliers and establishing strategic partnerships to support long-term sustainability.

(3) Procurement of Medical Equipment and Instruments

Medical equipment and instruments are critical factors in the provision of healthcare services. The Company places significant importance on the procurement of such equipment, with policies to source from reputable manufacturers and distributors that meet high standards of quality and safety, offer reasonable pricing, ensure timely delivery, and provide clear after-sales service agreements, thereby enabling efficient patient care.

In 2025, the Company procured medical equipment and instruments through domestic distributors in accordance with the aforementioned procurement policies. In addition, the Company collaborated with leading medical technology providers to establish the Gamma Knife Center, the first and only stereotactic radiosurgery center in Thailand utilizing the Leksell Gamma Knife technology, which is a global standard for the treatment of brain and neurological disorders without the need for open surgery.

During 2025, the Hospital also acquired several high-performance medical devices, including high-resolution ultrasound diagnostic systems, argon plasma coagulation units for gastrointestinal hemostasis, radiology display monitors, and an upgraded magnetic resonance imaging (MRI) system, GE Healthcare 1.5T SIGNA Explorer Lift, among others.

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Introduction

The company issued and offered for sale warrants to purchase its ordinary shares, totaling 1,123,729,289 units allocated to the company's existing ordinary shareholders, with the details of the offered warrants as follows:

Has Convertible Securities (Y/N)

Yes

Convertible Securities

Security NameIssued DateExercise Date(s)Maturity DateExercise PriceExercise RatioAllotted SharesConvertible SharesUnconverted SharesRemaining ConvertibleNotification Period
Warrant to Purchase Ordinary Shares of Vibhavadi Medical Center Public Company Limited Series 5 (VIBHA-W5)2025-12-15The last business day of March and September of each year2028-12-1421.000:1.0001,123,729,2891,123,729,2891,123,729,2891,123,729,289Within 5 business days prior to each exercise date.
Contents